253 related articles for article (PubMed ID: 25371286)
1. Comparison between biosimilar filgrastim vs other granulocyte-colony stimulating factor formulations (originator filgrastim, peg-filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network.
Marchesi F; Cerchiara E; Dessanti ML; Gumenyuk S; Franceschini L; Palombi F; Pisani F; Romano A; Spadea A; Pupo L; Annibali O; La Malfa A; Arcese W; Mengarelli A
Br J Haematol; 2015 Apr; 169(2):293-6. PubMed ID: 25371286
[No Abstract] [Full Text] [Related]
2. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
8. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
Marchesi F; Terrenato I; Papa E; Tomassi M; Falcucci P; Gumenyuk S; Palombi F; Pisani F; Renzi D; Romano A; Spadea A; Regazzo G; Rizzo MG; De Rienzo M; Ripellino C; Sgromo S; Viggiani C; Ponte E; Kayal R; Cordone I; Foddai ML; Mengarelli A
Ann Hematol; 2024 Mar; 103(3):947-956. PubMed ID: 38189833
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.
Schmitt M; Hoffmann JM; Lorenz K; Publicover A; Schmitt A; Nagler A
Vox Sang; 2016 Aug; 111(2):178-86. PubMed ID: 27509033
[TBL] [Abstract][Full Text] [Related]
11. Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation.
León-González M; León-Peña AA; Vallejo-VIllalobos MF; Núñez-Cortés AK; Ruiz-Argüelles A; Ruiz-Argüelles GJ
Rev Invest Clin; 2016; 68(4):181-3. PubMed ID: 27623036
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A
Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.
Ianotto JC; Ngo Sack F; Couturier MA; Tempescul A; Mugnier N; Delepine P; Guillerm G; Berthou C
Leuk Lymphoma; 2014 Jan; 55(1):74-7. PubMed ID: 23566160
[TBL] [Abstract][Full Text] [Related]
14. [Biosimilar filgrastim: from development to record].
García Alfonso P
Farm Hosp; 2010 Mar; 34 Suppl 1():19-24. PubMed ID: 20920854
[TBL] [Abstract][Full Text] [Related]
15. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar biologics: never identical but close enough.
Abi-Raad R; Smith BR
Transfusion; 2015 Feb; 55(2):229-31. PubMed ID: 25683185
[No Abstract] [Full Text] [Related]
17. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
[TBL] [Abstract][Full Text] [Related]
18. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.
Nicol C; Henry C; Couturier MA; Delépine P; Tripogney C; Buors C; Guillerm G; Berthou C; Tempescul A; Ianotto JC
Leuk Lymphoma; 2017 Sep; 58(9):1-3. PubMed ID: 28278727
[No Abstract] [Full Text] [Related]
20. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
Kim IH; Park SK; Suh OK; Oh JM
Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]